AMPLATZER™ LAA Occluder Post Approval Study (PAS)
NCT02964208
Arrhythmias, Cardiac, Atrial Fibrillation
Rosario, Santa Fe Province, Argentina
View Trial DetailsNCT Number: NCT01863979
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and its prevalence increases with aging of the population. It is reflected in the ECG recording by the replacement of regular P-waves by an undulating baseline and irregular ventricular complexes [2]. The uncoordinated atrial activity prevents effective atrial contraction, leading to clot formation. Atrial fibrillation contributes significantly to population morbidity and mortality, and presently available therapeutic approaches have major limitations, including limited efficacy and potentially serious side effects. It can be classified into one of the three following categories:
1. Paroxysmal: self-termination within 7 days 2. Persistent: requires termination by pharmacological or direct-current electric cardioversion 3. Permanent: restoration to sinus rhythm is impossible or inadvisable
It is believed that in many cases the natural history of AF involves evolution from paroxysmal to persistent to permanent forms through the influence of atrial remodeling caused by the arrhythmia itself and/or progression of underlying heart disease. As many underlying conditions contribute to the development and progression of AF, the full and exact mechanisms standing behind this common arrhythmia are not completely or sufficiently understood.
Thromboembolism is by far the most important complication of AF, and the most common factor in stroke in the elderly. The determinants of Virchow triad, including stasis, endothelial damage, and coagulation properties, are centrally involved in AF- related thrombus formation.
Hence, thorough searching for new possible causes or contributing factors for the developing and progression of AF and its most threatening complication, thromboembolism, is mandatory
The aim of the study is to look for new possible causes of atrial fibrillation and its complications.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
This is an observational historical prospective study. All patients admitted to the Rambam health care campus between 1.1.2007 and 31.11.2011 with the primary diagnosis with Acute Atrial Fibrillation and were 18 years old or older at the time of diagnosis, will be included in this historical prospective study.
Patients' demographic data, medical history, permanent medications, laboratory studies, electrocardiographic and echocardiographic reports will be collected from the radiologic information system; a computed medical registry.
After collecting the data, statistical analysis will be performed aiming to discover possible causes or predictors for atrial fibrillation development and the occurrence of its adverse complications, especially thromboembolism.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Time frame: 3 years
Time frame: 3 years
Rambam Health Care Campus
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02964208
Arrhythmias, Cardiac, Atrial Fibrillation
Rosario, Santa Fe Province, Argentina
View Trial DetailsNCT04499612
Arrhythmias, Cardiac, Atrial Fibrillation
Ryazan, Ryazan Oblast, Russia
View Trial DetailsNCT03803579
Anticoagulant-induced Bleeding, Arrhythmias, Cardiac
Cremona, Italy
View Trial DetailsNCT03854149
Anticoagulants Causing Adverse Effects in Therapeutic Use, Arrhythmias, Cardiac
Athens, Greece
View Trial Details